In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 151 to 175 of 425

Sort by

Type: GuidanceRemove Type: Guidance filter

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Ex-situ machine perfusion devices for deceased donor liver transplants	Health technology evaluation	20 August 2026
Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology tests	Diagnostics guidance	TBC
Familial Breast Cancer: initial assessment and genetic testing (update)	NICE guideline	22 April 2027
Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393]	Technology appraisal guidance	TBC
Fertility problems: assessment and treatment - update 1 and 2	NICE guideline	19 March 2026
Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071]	Technology appraisal guidance	TBC
Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]	Technology appraisal guidance	TBC
Finerenone for treating heart failure with preserved or mildly reduced ejection fraction [ID6514]	Technology appraisal guidance	4 June 2026
Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy [ID6133]	Technology appraisal guidance	TBC
Ganaxolone for adjunctive treatment of epilepsy associated with tuberous sclerosis complex with CDKL5 deficiency disorder [TSID12126]	Technology appraisal guidance	TBC
Gefurulimab for treating antibody-positive generalised myasthenia gravis [TSID12256]	Technology appraisal guidance	TBC
GID-MT567 Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain	Medical technologies guidance	TBC
Giredestrant with everolimus for treating oestrogen-receptor positive HER2-negative advanced breast cancer after cyclin-dependent kinase 4 and 6 inhibitor and endocrine treatment ID6576	Technology appraisal guidance	TBC
Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID5072]	Technology appraisal guidance	TBC
Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A ID6312	Technology appraisal guidance	TBC
Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323]	Technology appraisal guidance	TBC
Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis [ID6487]	Technology appraisal guidance	11 March 2026
Govorestat for treating classic galactosemia in people 2 to 65 years [TSID12071]	Technology appraisal guidance	TBC
Heart valve disease presenting in adults: investigation and management (transcatheter aortic valve implantation (TAVI) to treat aortic stenosis)	NICE guideline	TBC
Heart valve disease presenting in adults: investigation and management - transcatheter aortic valve implantation (TAVI) to treat aortic stenosis (update)	NICE guideline	TBC
Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]	Technology appraisal guidance	22 April 2026
Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]	Technology appraisal guidance	TBC
Ianalumab for treating active Sjogren's syndrome [ID6634]	Technology appraisal guidance	TBC
Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]	Technology appraisal guidance	TBC
Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable ID6596	Technology appraisal guidance	TBC

Results per page

10
25
50
All